InBody Co (041830) Fair Value & Analysis
Healthcare · KR · Market cap 723B KRW
Fair value as of: Jul 20, 2026
From 24 valuation models · updated 21 days ago
Share price +33.3% over the past month.
A solid business, but screening 29% overvalued on our models.
What matters now
- A high-quality business (quality 71/100), yet the market already pays well above fair value. Quality at a full price, with little margin of safety.
- The price sits above even our optimistic bull case (61,591 KRW). The favourable scenario is already priced in.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 20, 2026.
How to read this chart
60‑month range 16,777 KRW – 70,800 KRW · fair‑value band 37,377 KRW – 61,591 KRW · the 70,000 KRW price screens above the 49,984 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 20, 2026.
Analysis
InBody Co (041830) currently trades at 70,000 KRW, while our model-based Fair Value estimate is 49,984 KRW, implying the stock looks roughly 28.6% overvalued today. The Quality Score stands at 71/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, InBody Co generated revenue of 155B KRW at a net margin of 23.5%. Revenue grew 17.7% year over year. Fundamentals as of Jul 20, 2026
Our scenario range runs from 37,377 KRW (bear case) to 61,591 KRW (bull case); at 70,000 KRW, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades near its 52-week high and 213% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -11% fair-value upside, at -29%, 041830 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 24 models by family
Widest divergence: DCF Models (64,430 KRW) versus Asset-Based (15,795 KRW). Highest evidence: Growth DCF (80).
Notify me when 041830 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 20, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 68 · Market factors (momentum, volatility) 83
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
InBody Co.,Ltd provides body composition analysis solutions worldwide. The company offers body composition analyzers, blood pressure monitors, stadiometers, and body water analyzers, as well as InBody dial and bands. Its products are used in nephrology, liver disease, diabetes, nutrition, and rehabilitation applications.
Full company description
InBody Co.,Ltd provides body composition analysis solutions worldwide. The company offers body composition analyzers, blood pressure monitors, stadiometers, and body water analyzers, as well as InBody dial and bands. Its products are used in nephrology, liver disease, diabetes, nutrition, and rehabilitation applications. The company was formerly known as Biospace Co., Ltd. InBody Co.,Ltd was founded in 1996 and is headquartered in Seoul, South Korea.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
InBody Co reported revenue of 234B KRW in FY2025 versus 138B KRW in FY2021, a compound +14.1%/yr. Reported net income was 30.6B KRW in FY2025, compounding −2.6%/yr from FY2021.
041830 screens 29% overvalued. Compare with i-SENS, Inc →
Peer Group
Health Care · 2227 stocks
How this stock ranks against its sector: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median. (Industry “Healthcare Equipment & Supplies” was too small, so the broader sector is used.)
Valuation Multiples vs Health Care median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Healthcare Equipment & Supplies stocks, each showing price versus our Fair Value estimate (as of Jul 20, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| i-SENS, Inc 099190 | 15,270 KRW | 8,168 KRW | -47% |
| Value Added Technology Co 043150 | 16,800 KRW | 60,242 KRW | +259% |
| Mediana Co 041920 | 8,940 KRW | 6,289 KRW | -30% |
| Meta Biomed Co 059210 | 3,830 KRW | 9,875 KRW | +158% |
| Sewoon Medical Co 100700 | 2,245 KRW | 6,054 KRW | +170% |
| MEDIC MEDIC | 0.2100 PHP | 0.1400 PHP | -33% |
| MEKICS CO., Ltd 058110 | 1,780 KRW | 1,584 KRW | -11% |
| CU Medical Systems, Inc 115480 | 1,753 KRW | 1,134 KRW | -35% |
| PeopleBio, Inc 304840 | 857.00 KRW | 905.70 KRW | +6% |
| Novartis AG NVSN | 2,742 MXN | 2,379 MXN | -13% |
Compare InBody Co with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is InBody Co (041830) overvalued or undervalued?
What is the fair value of 041830?
What is the quality score of 041830?
What is the revenue of InBody Co (041830)?
What is the net profit margin of 041830?
Does InBody Co pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track InBody Co and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.